Cytolysis of malignant glioma cells by lymphokine-activated killer cells combined with anti-CD3/antiglioma bifunctional antibody and tumor necrosis factor-α

Journal of Surgical Oncology

Volumn 62, Issue 3, 1996, Pages 177-182

  Yoshida, Jun ^a   Takaoka, Toru ^a   Mizuno, Masaaki ^a,b   Momota, Hiroshi ^c   Okada, Hidechika ^c  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c NAGOYA CITY UNIV MEDICAL SCHOOL   (Japan)

Author keywords

bifunctional antibody; glioma; ICAM 1; TNF

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; MONOCLONAL ANTIBODY CD3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CELL INTERACTION; CYTOLYSIS; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; KILLER CELL; LYMPHOCYTE ACTIVATION; PRIORITY JOURNAL;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIGENS, CD3; CYTOTOXICITY, IMMUNOLOGIC; FLOW CYTOMETRY; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERCELLULAR ADHESION MOLECULE-1; KILLER CELLS, LYMPHOKINE-ACTIVATED; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0029959353     PISSN: 00224790     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9098(199607)62:3<177::AID-JSO6>3.0.CO;2-4     Document Type: Article

References (31)

1. Grimm EA, Mazumber A, Zhang HZ, et al.: Lymphokine-activated killer cell phenomenon: Lysis of fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 155:1823-1841, 1982.
2. Jacobs SK, Wilson DJ, Kornblith PL, et al.: Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report. J Neurosurg 64:743-749, 1986.
3. Rosenberg SA, Lotze MT, Muul LM, et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokineactivated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889-897, 1987.
4. Barba D, Saris SC, Holder C, et al.: Intratumoral LAK cell and interleukin-2 therapy of human gliomas. J Neurosurg 70:175-182, 1989.
5. Jacobs SK, Wilson DJ, Kornblith PL, et al.: Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: Phase I trial. Cancer Res 46:2101-2104, 1986.
6. Bodmer S, Strommer K, Frei K, et al.: Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J Immunol 143:3222-3229, 1989.
7. Kuppner MC, Hamou MF, Sawamura Y, et al.: Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor β2. J Neurosurg 71:211-217, 1989.
8. Fady C, Gardner AM, Gera JF, et al.: Interferon-induced increase in sensitivity of ovarian cancer targets to lysis by lymphokine-activated killer cells: Selective effects on HER2/neu-over expressing cells. Cancer Res 52:764-769, 1992.
9. Naganuma H, Kiessling R, Patarroyo M, et al.: Increased susceptibility of IFN-γ-treated neuroblastoma cells to lysis by lymphokineactivated killer cells: Participation of ICAM-1 induction on target cells. Int J Cancer 47:527-532, 1991.
10. Nitta T, Sato K, Yagita H, et al.: Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335:368-371, 1990.
11. Mizuno M, Yoshida J, Takaoka T, et al.: Reinforced cytotoxicity of lymphokine-activated killer cells toward glioma cells by transfection of the killer cells with the γ-interferon gene. Jpn J Cancer Res 86:95-100, 1995.
12. Takaoka T, Yoshida J, Mizuno M, et al.: Transfection-induced tumor necrosis factor-a increases the susceptibility of human glioma cells to lysis by lymphokine-activated killer cells: Continuous expression of intercellular adhesion molecule-1 on the glioma cells. Jpn J Cancer Res 85:750-755, 1994.
13. Mizuno M, Yoshida J, Takaoka T, et al.: Liposomal transfection of human γ-interferon gene into human glioma cells and adoptive immunotherapy using lymphokine-activated killer cells. J Neurosurg 80:510-514, 1994.
14. Obukhov SK, Gennie MJ, Tutt AL, et al.: The cytotoxic action of lymphokine-activated killer cells upon the human glioma cell line U251 is stimulated by bispecific monoclonal antibody (MoAb) constructs. J Neurooncol 13:203-210, 1992.
15. Yoshida J, Wakabayashi T, Mizuno M, et al.: Clinical effect of intraarterial tumor necrosis factor-α for malignant glioma. J Neurosurg 77:78-83, 1992.
16. Wakabayashi T, Yoshida J, Seo H, et al.: Characterization of neuroectodermal antigen by a monoclonal antibody and its application in CSF diagnosis of human glioma. J Neurosurg 68:449-455,1988.
17. 2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent induction of cytolysis of human T cells. Eur J Immunol 19:1437-1441, 1989.
18. Hook GR, Greenwood MA, Barba D, et al.: Morphology of interleukin-2-stimulated human peripheral blood mononuclear effector cells killing glioma-derived tumor cells in vitro. J Natl Cancer Inst 80:171-177, 1988.
19. Apasov S, Redegeld F, Sitkosv M: Cell-mediated cytotoxicity: Contact and secreted factors. Curr Opin Immunol 5:404-410, 1993.
20. Ojcius DM, Zheng LM, Sphicas EC, et al.: Subcellular localization of perform and serine esterase in lymphokine-activated killer cells and cytotoxic T cells by immunogold labeling. J Immunol 146:4427-4432, 1991.
21. Helgason CD, Shi L, Greenberg AH, et al.: DNA fragmentation induced by cytotoxic T lymphocytes can result in target cell death. Exp Cell Res 206:302-310, 1993.
22. Laster SM, Wood JG, Gooding LR: Tumor necrosis factor can induce both apoptic and necrotic forms of cell lysis. J Immunol 141:2629-2634, 1988.
23. Mizuno M, Yoshida J, Oyama H, et al.: Growth inhibition of glioma cells by liposome-mediated cell transfection with tumor necrosis factor-a gene. Neurol Med Chir (Tokyo) 32:873-876, 1992.
24. Owen Schaub LB, Yonehara S, Crump WL, et al.: DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement. Cell Immunol 140:197-205, 1992.
25. Marlin SD, Springer TA: Purified intercellular adhesion molecule1 (ICAM-1) is a ligand for lymphocyte function associated antigen (LFA-1). Cell 51:813-819, 1987.
26. Azuma A, Yagita H, Matsuda H, et al.: Induction of intercellular adhesion molecule 1 on small cell lung carcinoma cell lines by γ-interferon enhances spontaneous and bispecific anti-CD3 × antitumor antibody-directed lymphokine-activated killer cell cytotoxicity. Cancer Res 52:4890-4894, 1992.
27. Mahaley MS Jr, Bertsch L, Cush S, et al.: Systemic gamma-interferon therapy for recurrent gliomas. J Neurosurg 69:826-829, 1988.
28. Nitta T, Sato K, Okumura K, et al.: Induction of cytotoxicity in human T cells coated with anti-glioma × anti-CD3 bispecific antibody against human glioma cells. J Neurosurg 72:476-481, 1990.
29. Yoshida J, Wakabayashi T, Mizuno M, et al.: Tumor-specific binding of radiolabelled G-22 monoclonal antibody in glioma patients. Neurol Med Chir (Tokyo) 32:125-129, 1992.
30. Salmeron A, Sanchez-Madrid F, Ursa MA, et al.: A conformational epitope expressed upon association of CD3-∈ with either CD3-δ or CD3-γ is the main target for recognition by anti-CD3 monoclonal antibodies. J Immunol 147:3047-3052, 1991.
31. Dixon JFP, Law JL, Favero JJ: Activation of human T lymphocyte by cross linking of anti-CD3 monoclonal antibodies. J Leukocyte Biol 46:214-220, 1989.